AJANTPHARM · Ajanta Pharma Ltd · Biotechnology & Drugs
AJANTPHARM · Ajanta Pharma Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
13.5% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹1,626 Cr
Revenue YoY
PAT YoY
+30.9%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
9.7
P/S (TTM)
7.6
Sector P/E
36.3
Dividend yield
+0.8%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| AJANTPHARM (this stock) | 37.7 | 9.7 | +19.6% | +25.1% | 0.06 | +0.8% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
falling 1q
FII
falling 1q
MF
18.10% (+2.88pp)
rising 1q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 29 Jun 2026 | JAGDISH DWARKADAS JOSHI | SELL | 725 | ₹24.14 lakh |
| 29 Jun 2026 | A V JAYAKUMAR | SELL | 2,500 | ₹81.78 lakh |
| 29 Jun 2026 | JAGDISH DWARKADAS JOSHI | SELL | 725 | ₹24.14 lakh |
| 29 Jun 2026 | A V JAYAKUMAR | SELL | 2,500 | ₹81.78 lakh |
| 09 Jun 2026 | RAVI P AGRAWAL, TRUSTEE RAVI AGRAWAL TRUST | SELL | 34,50,000 | ₹1,024 Cr |
| 02 Jun 2026 | GABS INVESTMENTS PVT LTD | SELL | 27,70,000 | ₹808 Cr |
| 02 Jun 2026 | AAYUSH M AGRAWAL, TRUSTEE AAYUSH AGRAWAL TRUST | SELL | 28,55,925 | ₹833 Cr |
| 12 Nov 2025 | SHAILESH R SINGH | SELL | 2,000 | ₹51.31 lakh |
| 11 Nov 2025 | SHAILESH R SINGH | SELL | 3,000 | ₹75.85 lakh |
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| AJANTPHARM | 2026-06-09 | 2102291 | 1 | STRONG | BULK |
News timeline
- loweconomictimes.indiatimes.com· 18 Aug 2026, 05:21 pmAjanta Pharma among 5 midcap stocks to hit 52-week highs & surge up to 18% in a month - Fresh Highs
- mediummacroeconomictimes.indiatimes.com· 17 Aug 2026, 09:32 pmAhead of Market: 10 things that will decide stock market action on Tuesday
- loweconomictimes.indiatimes.com· 17 Aug 2026, 05:09 pmKEI Industries among 4 midcap stocks to hit 52-week highs & surge up to 15% in a month - New Peaks
- mediumeconomictimes.indiatimes.com· 13 Aug 2026, 09:29 pmAhead of Market: 10 things that will decide stock market action on Friday
- lowthehindubusinessline.com· 31 Jul 2026, 09:07 pmQ1 Results Today : Bajaj Finserv, Sun Pharma, GAIL, Dixon Tech, Aether, Glenmark Q1 profit rise, Urban Company logs Q1 loss, Maruti Suzuki, ITC, IOC Q1 profit declines
- highsector policyeconomictimes.indiatimes.com· 23 Jul 2026, 05:29 amPharma stocks slide as Trump's 100% generic drug tariff plan spooks investors
Concalls & investor presentations
AI-generatedKey takeaway: Ajanta Pharma Limited provided a written transcript of its earnings call held on 30th October 2026, as required by SEBI regulations. The transcript is available on the company's website at the specified link. The document does not include specific financial results, operational updates, or management commentary from the call. It serves as a formal disclosure to stakeholders, confirming the availability of the earnings call transcript for reference. No details about the discussion or performance metrics were included in this filing.
The tone is neutral as the document only confirms the availability of the transcript without providing specific content or commentary from the call.
Sourced from an exchange-filed transcript, dated 04 Nov 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Ajanta Pharma Limited provided a written transcript of its earnings call conducted on July 30, 2026. The document included details regarding the call's timing and the company's compliance with SEBI regulations. It was noted that the transcript is available on the company's website for public access. The communication was signed by Gaurang Shah, Senior Vice President – Legal & Company Secretary, and dated August 3, 2026.
The document presented factual information regarding the earnings call and compliance without emphasizing any particular sentiment.
Sourced from an exchange-filed transcript, dated 03 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Ajanta Pharma Limited provided a written transcript of its earnings call conducted on May 5, 2026. The document included details regarding the call and was made available on the company's website for public access. The communication was in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Gaurang Shah, the Senior Vice President – Legal & Company Secretary, signed the document digitally, confirming its authenticity and submission to BSE and NSE.
The document presented factual information regarding the earnings call and compliance without emphasizing any particular sentiment.
Sourced from an exchange-filed transcript, dated 08 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Ajanta Pharma Limited provided a written transcript of its earnings call conducted on January 30, 2026. The document confirmed that the transcript is available on the company's website for public access. The communication was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Gaurang Shah, the Senior Vice President – Legal & Company Secretary, signed the document digitally, indicating the formal nature of the communication.
The document presented factual information regarding the earnings call and its transcript availability.
Sourced from an exchange-filed transcript, dated 05 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedAjanta Pharma Limited reported strong financial performance in FY2026 with revenue of ₹5,453 crore, EBITDA of ₹1,498 crore, and PAT of ₹1,056 crore. The company emphasized growth in Branded Generics, US Generics, and Africa Institutional businesses, with significant new product launches and market expansion. The audit highlighted a tax authority search and notice related to a block period, but no material impact on financials was confirmed. The company maintains robust internal controls and governance practices, with no defaults or regulatory actions noted.
- Revenue grew to ₹5,453 crore in FY2026, with Branded Generics contributing 68% of total revenue.
- US Generics business saw 49% growth, driven by 8 new product launches.
- Audit noted a tax authority search in August 2025 and a notice under Section 158BC of the Income Tax Act, but no material impact on financials was confirmed.
- No defaults in loan payments or regulatory actions affecting going-concern status were reported.
- The company has strong internal controls and governance, with no material disputes or contingent liabilities noted.
Key takeaway: Ajanta Pharma delivered strong financial performance in FY2026 with robust growth across key business segments, though a pending tax authority inquiry remains a potential risk.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceRecent (last 12 months)
The auditor drew attention to a search by Income Tax Authorities in August 2025 and a notice under Section 158BC of the Income-tax Act, 1961 for the block period 1 April 2019 to 17 November 2025. The company filed the return on 6 April 2026, and the impact on the financial statements is not yet ascertainable.
Default / Covenant Breach
1 occurrenceOlder (3+ years ago)
The company has undisputed statutory dues in arrears for more than six months as of 31 March 2022, including Goods and Service Tax (GST), Sales Tax, Value Added Tax, and Duty of Excise.
Routine disclosures
Internal Control Weakness
1 occurrenceRecent (last 12 months)
The auditor mentions evaluating the operating effectiveness of internal financial controls and communicating any significant deficiencies identified during the audit.
Contingent Liability
4 occurrencesRecent (last 12 months)
The company has two ongoing patent litigations as of 31 March 2026, with no liability expected to arise from these litigations.
Earlier (1-3 years ago)
The company has pending customs duty claims under the Advance License Scheme due to unfulfilled export obligations and disputed octroi payments, with ₹0.52 Crore paid under protest as of 31 March 2023.
Older (3+ years ago)
The company has contingent liabilities including disputed octroi amount paid under protest (₹0.52 Crore as of 31 March 2022) and customs duty on import under Advance License Scheme pending fulfillment of export obligations.
The company has three ongoing patent litigations as of 31 March 2022, with no liability expected to arise from these litigations.
Related-Party Transaction
1 occurrenceEarlier (1-3 years ago)
The company has ongoing patent litigations as of 31 March 2024, with no liability expected from these litigations.
Statutory dues in dispute
3 occurrencesRecent (last 12 months)
The company has amounts not deposited under dispute for Goods and Service Tax for FY 2017-18, pending before CESTAT in Hyderabad and Palghar.
Earlier (1-3 years ago)
Ajanta Pharma Limited has statutory dues under dispute for Goods and Service Tax, Excise duty, and other taxes, with amounts not deposited pending resolution before various CESTAT and Joint Commissioner Appeals forums.
Older (3+ years ago)
The company has statutory dues in dispute, including Goods and Service Tax, Excise duty, and CST, with amounts not deposited under dispute as of FY 2017-18 and other periods, pending before various CESTAT and Joint Commissioner Appeals forums.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
15.01% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18). Change vs the previous disclosure: increasing.